Tenofovir Alafenamide Fumarate 25 mg (Vemlidy) is a medication used primarily for the treatment of chronic hepatitis B (HBV) and HIV-1 infection. It is marketed under the brand name Vemlidy and belongs to the class of nucleotide reverse transcriptase inhibitors (NRTIs). Tenofovir alafenamide works by inhibiting the reverse transcriptase enzyme, which is crucial for the replication of both HIV and hepatitis B virus.

Tenofovir Alafenamide Fumarate 25 mg (Vemlidy)

Product Overview: Tenofovir Alafenamide Fumarate 25 mg (Vemlidy) is an antiviral medication used for the treatment of chronic hepatitis B (HBV) in adults and for the management of HIV-1 infection in combination with other antiretroviral agents. Vemlidy is a nucleotide reverse transcriptase inhibitor (NRTI) that works by inhibiting the replication of HIV and HBV, preventing the virus from multiplying and reducing the impact of the infection.

Key Benefits:

• Effective treatment for chronic hepatitis B (HBV) in adult patients.
• Also used as part of combination therapy for HIV-1 infection.
• Lower dose with fewer side effects compared to older tenofovir formulations, due to improved delivery of the active ingredient.
• Convenient once-daily oral dose, taken with or without food.
• Renal and bone safety profile: The newer formulation is associated with a lower risk of kidney and bone toxicity compared to older tenofovir formulations.

Indications:

• Chronic hepatitis B (HBV) in adults with evidence of active viral replication and liver inflammation.
• As part of a combination regimen for the treatment of HIV-1 infection in adults and children (at least 12 years old).

Dosage:

• The typical dose of Vemlidy (Tenofovir Alafenamide 25 mg) is one tablet once daily.
• It can be taken with or without food, making it a convenient treatment option.
• Dosage adjustments may be necessary for patients with renal impairment, and kidney function should be monitored regularly.

Precautions:

• Kidney function: Tenofovir alafenamide can affect kidney function. Regular monitoring of renal function is recommended, especially in patients with pre-existing kidney conditions.
• Bone health: Long-term use of antiviral medications may affect bone mineral density. Regular bone health monitoring may be required.
• HIV resistance: Vemlidy is not recommended for the treatment of HIV-1 alone. It should be used in combination with other antiretroviral agents.
• Not recommended during pregnancy unless the benefits outweigh the risks. Use in pregnant women should be discussed with a healthcare provider.

Common Side Effects:

• Headache
• Fatigue
• Nausea
• Abdominal pain
• Diarrhea
• Decreased bone mineral density (with long-term use)
• Renal issues (e.g., changes in creatinine levels)

Packaging:

• Tenofovir Alafenamide Fumarate 25 mg (Vemlidy) tablets are available in a [insert packaging type], ensuring secure and easy access for patients.

Important Notes:

• Adherence to treatment: It’s important to take Vemlidy exactly as prescribed to ensure the effectiveness of the treatment.
• Monitor regularly: Regular check-ups, including renal function, liver enzymes, and bone density tests, are essential to manage potential side effects and ensure the safety of long-term use.
• Storage: Store Vemlidy in a cool, dry place, away from sunlight, and keep out of reach of children.